On Monday, Nexalin Technology, Inc. (NASDAQ:NXL) announced the publication of a study in the Journal of Alzheimer’s Disease.

The study builds on recent findings from Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease (AD).

The new research involved 46 randomly assigned patients receiving either real DIFS or sham treatment for 30 one-hour sessions over three weeks.

Resting-state functional magnetic resonance imaging (rs-fMRI) was used to track changes in brain activity.

Key Findings of the Study Include:

• Patients receiving real DIFS exhibited significant increases in the fractional amplitude of low-frequency fluctuation (fALFF) in key brain areas, such as the prefrontal cortex.
• fALFF, which measures regional spontaneous neuronal activity, has been shown to correlate with glucose metabolism, a crucial process for cognitive function that is often impaired in Alzheimer’s patients, suggesting that DIFS may help restore metabolic functions within the brain, contributing to improved cognition.
• After three weeks of treatment, patients showed improvements in cognitive function. Increased neuronal activity was observed in regions such as the superior parietal lobule and inferior temporal gyrus, both critical for memory and cognitive processing.
• The study found improvements in regional homogeneity (ReHo) in the left middle frontal and right superior medial frontal gyrus, indicating better synchronization of neural activity between different brain regions.
• Enhanced blood flow was observed in several critical regions, correlating with increased neuronal activity.

The study indicated no serious side effects reported among participants.

Despite undergoing twice-daily stimulation sessions over three weeks, elderly patients tolerated the treatment well, with only minor sensations such as tingling that resolved quickly.

The company adds that Alzheimer’s disease affects over 50 million people globally, and it is projected to rise to over 113 million by 2050.

Price Action: NXL stock is down 4.37% at $2.19 during the premarket session at last check Monday.

Read Next:

• Elbit Systems Secures $200M Contract For High-Power Laser Defense; Stock Gains.

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

This article EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.